C6 ceramide sensitizes pemetrexed-induced apoptosis and cytotoxicity in osteosarcoma cells

Biochemical and Biophysical Research Communications

Volumn 452, Issue 1, 2014, Pages 72-78

  Zhu, Xinhui ^a   Du, Xueping ^b   Deng, Xiaolong ^a   Yi, Hong ^a   Cui, Shengyu ^a   Liu, Wei ^a   Shen, Aiguo ^c   Cui, Zhiming ^a  

^a NANTONG UNIVERSITY   (China)

^b Department of Orthopaedics Qi Dong Hospital of Traditional Chinese Medicine   (China)

^c NANTONG MEDICAL COLLEGE   (China)

Author keywords

Akt mTOR signaling and chemo sensitization; C6 ceramide; Osteosarcoma; Pemetrexed

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; C6 CERAMIDE; CERAMIDE; MAMMALIAN TARGET OF RAPAMYCIN; PEMETREXED; PROTEIN KINASE B; S6 KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; GLUTAMIC ACID DERIVATIVE; GUANINE;

3T3 CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; OSTEOSARCOMA CELL; OSTEOSARCOMA CELL LINE; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENETICS; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CERAMIDES; GLUTAMATES; GUANINE; HUMANS; OSTEOSARCOMA; RNA, SMALL INTERFERING;

EID: 84907814461     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.08.065     Document Type: Article

References (42)

1. N. Jaffe Osteosarcoma: review of the past, impact on the future. The American experience Cancer Treat. Res. 152 2009 239 262
2. A.M. Davis, R.S. Bell, and P.J. Goodwin Prognostic factors in osteosarcoma: a critical review J. Clin. Oncol. 12 1994 423 431
3. J.C. Clark, C.R. Dass, and P.F. Choong A review of clinical and molecular prognostic factors in osteosarcoma J. Cancer Res. Clin. Oncol. 134 2008 281 297
4. M.L. Broadhead, J.C. Clark, D.E. Myers, C.R. Dass, and P.F. Choong The molecular pathogenesis of osteosarcoma: a review Sarcoma 2011 2011 959248
5. L.R. Villela, B.L. Stanford, and S.R. Shah Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy Pharmacotherapy 26 2006 641 654
6. K.D. Rollins, and C. Lindley Pemetrexed: a multitargeted antifolate Clin. Ther. 27 2005 1343 1382
7. C. Genova, E. Rijavec, A. Truini, S. Coco, C. Sini, G. Barletta, M.G. Dal Bello, A. Alama, G. Savarino, P. Pronzato, F. Boccardo, and F. Grossi Pemetrexed for the treatment of non-small cell lung cancer Expert Opin. Pharmacother. 14 2013 1545 1558
8. J.B. Sorensen, S. Sundstrom, K. Perell, and A.K. Thielsen Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment J. Thorac. Oncol. 2 2007 147 152
9. N. Bodmer, D.K. Walters, and B. Fuchs Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines Pediatr. Blood Cancer 50 2008 905 908
10. M.T. Dimanche-Boitrel, A. Rebillard, and E. Gulbins Ceramide in chemotherapy of tumors Recent Patent Anticancer Drug Discov. 6 2011 284 293
11. M.M. Young, M. Kester, and H.G. Wang Sphingolipids: regulators of crosstalk between apoptosis and autophagy J. Lipid Res. 54 2013 5 19
12. S.A. Morad, and M.C. Cabot Ceramide-orchestrated signalling in cancer cells Nat. Rev. Cancer 13 2013 51 65
13. B. Henry, C. Moller, M.T. Dimanche-Boitrel, E. Gulbins, and K.A. Becker Targeting the ceramide system in cancer Cancer Lett. 2011
14. C. Ji, B. Yang, Y.L. Yang, S.H. He, D.S. Miao, L. He, and Z.G. Bi Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition Oncogene 29 2010 6557 6568
15. Q.Y. Zhu, Z. Wang, C. Ji, L. Cheng, Y.L. Yang, J. Ren, Y.H. Jin, Q.J. Wang, X.J. Gu, Z.G. Bi, G. Hu, and Y. Yang C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and alpha-tubulin hyperacetylation both in vitro and in vivo Cell Death Dis. 2 2011 e117
16. Y.F. Zhen, G.D. Wang, L.Q. Zhu, S.P. Tan, F.Y. Zhang, X.Z. Zhou, and X.D. Wang P53 dependent mitochondrial permeability transition pore opening is required for dexamethasone-induced death of osteoblasts J. Cell. Physiol. 2014
17. J.B. Fan, W. Liu, K. Yuan, X.H. Zhu, D.W. Xu, J.J. Chen, and Z.M. Cui EGFR trans-activation mediates pleiotrophin-induced activation of Akt and Erk in cultured osteoblasts Biochem. Biophys. Res. Commun. 447 2014 425 430
18. M. Toulany, U. Kasten-Pisula, I. Brammer, S. Wang, J. Chen, K. Dittmann, M. Baumann, E. Dikomey, and H.P. Rodemann Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair Clin. Cancer Res. 12 2006 4119 4126
19. D. Gao, H. Inuzuka, A. Tseng, R.Y. Chin, A. Toker, and W. Wei Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction Nat. Cell Biol. 11 2009 397 408
20. C. Yao, S. Wu, D. Li, H. Ding, Z. Wang, Y. Yang, S. Yan, and Z. Gu Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro Mol. Oncol. 6 2012 392 404
21. T.Y. Yang, G.C. Chang, K.C. Chen, H.W. Hung, K.H. Hsu, C.H. Wu, G.T. Sheu, and S.L. Hsu Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways Mol. Carcinog. 52 2013 183 194
22. A. Buque, J. Muhialdin, A. Munoz, B. Calvo, S. Carrera, U. Aresti, A. Sancho, I. Rubio, and G. Lopez-Vivanco Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells Mol. Cancer 11 2012 25
23. M.W. Craighead, P. Tiwari, R.G. Keynes, and C.M. Waters Human oligodendroglial cell line, MO3.13, can be protected from apoptosis using the general caspase inhibitor zVAD-FMK J. Neurosci. Res. 57 1999 236 243
24. J. Yang, and W. Zhang New molecular insights into osteosarcoma targeted therapy Curr. Opin. Oncol. 25 2013 398 406
25. C.F. Lin, C.L. Chen, and Y.S. Lin Ceramide in apoptotic signaling and anticancer therapy Curr. Med. Chem. 13 2006 1609 1616
26. J.J. Gills, and P.A. Dennis Perifosine: update on a novel Akt inhibitor Curr. Oncol. Rep. 11 2009 102 110
27. H.Z. Huo, Z.Y. Zhou, B. Wang, J. Qin, W.Y. Liu, and Y. Gu Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014 Biochem. Biophys. Res. Commun. 443 2014 406 412
28. Y. Qiu, T. Yu, W. Wang, K. Pan, D. Shi, and H. Sun Curcumin-induced melanoma cell death is associated with mitochondrial permeability transition pore (mPTP) opening Biochem. Biophys. Res. Commun. 2014
29. Y. Al Dhaheri, S. Attoub, K. Arafat, S. Abuqamar, A. Eid, N. Al Faresi, R. Iratni Al Faresi, and R. Iratni Salinomycin induces apoptosis and senescence in breast cancer: upregulation of p21, downregulation of survivin and histone H3 and H4 hyperacetylation Biochim. Biophys. Acta 1830 2013 3121 3135
30. N.J. Curtin, and A.N. Hughes Pemetrexed disodium, a novel antifolate with multiple targets Lancet Oncol. 2 2001 298 306
31. Q. Li, K. Kawamura, M. Yamanaka, S. Okamoto, S. Yang, S. Yamauchi, T. Fukamachi, H. Kobayashi, Y. Tada, Y. Takiguchi, K. Tatsumi, H. Shimada, K. Hiroshima, and M. Tagawa Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed Cancer Gene Ther. 19 2012 218 228
32. T.Y. Yang, G.C. Chang, K.C. Chen, H.W. Hung, K.H. Hsu, G.T. Sheu, and S.L. Hsu Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells Eur. J. Pharmacol. 663 2011 17 26
33. S.B. Rothbart, A.C. Racanelli, and R.G. Moran Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas Cancer Res. 70 2010 10299 10309
34. F. Duffaud, G. Egerer, S. Ferrari, H. Rassam, U. Boecker, and B. Bui-Nguyen A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma Eur. J. Cancer 48 2012 564 570
35. C.H. Wu, C. Cao, J.H. Kim, C.H. Hsu, H.J. Wanebo, W.D. Bowen, J. Xu, and J. Marshall Trojan-horse nanotube on-command intracellular drug delivery Nano Lett. 12 2012 5475 5480
36. A. Giatromanolaki, E. Sivridis, C. Simopoulos, A. Polychronidis, K.C. Gatter, A.L. Harris, and M.I. Koukourakis Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas J. Surg. Oncol. 94 2006 242 247
37. B.T. Hennessy, D.L. Smith, P.T. Ram, Y. Lu, and G.B. Mills Exploiting the PI3K/AKT pathway for cancer drug discovery Nat. Rev. Drug Discov. 4 2005 988 1004
38. T. Li, Y.H. Ling, I.D. Goldman, and R. Perez-Soler Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells Clin. Cancer Res. 13 2007 3413 3422
39. E. Giovannetti, P.A. Zucali, Y.G. Assaraf, L.G. Leon, K. Smid, C. Alecci, F. Giancola, A. Destro, L. Gianoncelli, E. Lorenzi, M. Roncalli, A. Santoro, and G.J. Peters Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin Br. J. Cancer 105 2011 1542 1553
40. R.T. Dobrowsky, C. Kamibayashi, M.C. Mumby, and Y.A. Hannun Ceramide activates heterotrimeric protein phosphatase 2A J. Biol. Chem. 268 1993 15523 15530
41. B. Law, and S. Rossie The dimeric and catalytic subunit forms of protein phosphatase 2A from rat brain are stimulated by C2-ceramide J. Biol. Chem. 270 1995 12808 12813
42. R.A. Wolff, R.T. Dobrowsky, A. Bielawska, L.M. Obeid, and Y.A. Hannun Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction J. Biol. Chem. 269 1994 19605 19609